FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

Evidence for efficacy was evaluated in the ARCHES trial
03 Jan 2020
Anticancer agents & Biologic therapy;  Genitourinary cancers

On 16 December 2019, the US Food and Drug Administration (FDA) approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).

FDA previously approved enzalutamide for patients with castration-resistant prostate cancer.

Efficacy was investigated in ARCHES (NCT02677896), a trial enrolling1150 patients with mCSPC randomised (1:1) to receive either enzalutamide orally 160 mg once daily (n=574) or placebo orally once daily (n=576). All patients received a GnRH analogue or had a prior bilateral orchiectomy.

The main efficacy outcome measure was radiographic progression-free survival (rPFS). Based on blinded independent central review, rPFS was defined as the time from randomisation to radiographic disease progression at any time or death within 24 weeks after drug discontinuation. Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 2 criteria) and/or progression in soft tissue disease. Time to new antineoplastic therapy was an additional endpoint.

Median rPFS was not reached (NR) in the enzalutamide arm compared to 19.4 months (95% CI: 16.6, NR) in the placebo arm (HR 0.39; 95% CI: 0.30, 0.50; p < 0.0001). A statistically significant improvement was also reported on the enzalutamide arm compared to placebo in time to initiation of a new antineoplastic therapy (HR 0.28; 95% CI: 0.20, 0.40; p < 0.0001). Overall survival data were not mature at the time of rPFS analysis.

The most common adverse reactions (≥ 5%) that occurred more frequently (≥ 2% over placebo) in enzalutamide-treated patients in ARCHES were hot flush, asthenia/fatigue, hypertension, fractures, and musculoskeletal pain.

The recommended dose is 160 mg (four 40 mg capsules) administered orally once daily, with or without food.

Full prescribing information for XTANDI is available here.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate FDA’s assessment. This application was approved two weeks prior to the FDA goal date.

Enzalutamide was granted priority review.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings